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The Molecular Karyotype of 25 
Clinical-Grade Human Embryonic 
Stem Cell Lines
Maurice A. Canham1, Amy Van Deusen1, Daniel R. Brison2, Paul A. De Sousa3,4, 
Janet Downie3, Liani Devito5, Zoe A. Hewitt6, Dusko Ilic5, Susan J. Kimber7, 
Harry D. Moore6, Helen Murray3 & Tilo Kunath1
The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now 
becoming a reality. Although the vast majority of hESC lines have been derived for research purposes 
only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. 
Cell types differentiated from these designated lines may be used as a cell therapy to treat macular 
degeneration, Parkinson’s, Huntington’s, diabetes, osteoarthritis and other degenerative conditions. 
It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. 
We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single 
nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) 
greater than 100 kb were detected, most of which were found to be naturally occurring in the human 
population and none were associated with culture adaptation. In addition, three copy-neutral loss 
of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small 
and interstitial suggesting they did not arise in culture. The large number of available clinical-grade 
hESC lines with defined molecular karyotypes provides a substantial starting platform from which the 
development of pre-clinical and clinical trials in regenerative medicine can be realised.
Since the derivation of human embryonic stem cells (hESCs) from blastocysts in 19981, and the more 
recent production of human induced pluripotent stem cells (iPSCs) from adult tissues2, anticipation has 
been growing with regard to their potential as cell therapies for a number of incurable conditions. As 
with any new medicine, Good Manufacturing Practice (GMP) is required to produce hESC/iPSC-derived 
cell products for clinical use in humans3. However, while over 1200 hESC lines have been established 
and reported worldwide4, the majority are suitable only for research purposes due to the sourcing of 
embryonic material, derivation process and subsequent handling procedures. Frequently, derivation and 
culture methods employ mouse feeder cells or poorly defined media containing animal-based products1,5, 
which may render these cell lines unusable as a starting material for any cell-based clinical application.
In recent years, there have been advances in the derivation of hESC lines whereby fully defined media 
devoid of animal-derived products is used6,7, and the traditional mouse feeders have been replaced with 
GMP-qualified human feeders8–10 or recombinant human proteins as a substrate on which to culture 
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hESCs11–14. Furthermore, animal-based enzymes and guinea pig complement used to isolate the inner 
cell mass for hESC derivation have been replaced with mechanical isolation or laser microdissection15–19. 
These efforts have culminated in the derivation of approximately 50 clinical-grade hESC lines from var-
ious centres across the world20–23 (www.mrc.ac.uk/research/facilities/stem-cell-bank; stemcells.nih.gov).
Remarkably, 38 of these lines have been derived among five different centres in the United Kingdom 
through funding from the Medical Research Council (MRC), Scottish Enterprise, the North West 
Development Agency and the Juvenile Diabetes Research Foundation. The MRC launched an initiative in 
2005 to provide infrastructure funding to UK in vitro fertilization (IVF) units to provide GMP-compliant 
embryos for hESC line derivation and further funded the Human Embryonic Stem Cell Co-ordinators 
(hESCCO) network, subsequently the National Clinical hESC Forum. This allowed the derivation centres 
to work with the Human Fertilisation and Embryology Authority and the UK Stem Cell Bank to estab-
lish common parameters for patient consent, screening and embryo procurement for the derivation of 
clinical-grade hESC lines. Ultimately this farsighted policy has yielded a cohort of hESC lines which have 
benefited from the shared implementation of GMP-compliant IVF laboratory standards, hESC derivation 
procedures and ethical principles for donor consenting24. A list of clinical-grade hESC lines conforming 
to the European Union Tissue and Cells Directives (Directives 2004/23/EC and 2006/17/EC) is shown 
in Table 1. These directives introduced common safety and quality standards across European member 
states to ensure that all tissues and cells used in patient treatment are traceable from donor to recipient, 
thus implementing key principles of GMP.
The value of a large number of different cell lines as starting material for clinical applications is 
three-fold: (a) different hESC lines have varying propensities to generate specific cell lineages during in 
vitro differentiation25, (b) hESC lines may harbour or acquire genetic anomalies potentially excluding 
them from clinical use26, and (c) in order to accommodate human leucocyte antigen (HLA) matching 
to a broad section of potential patients a sizeable number of hESC lines would be required. It has been 
estimated that approximately 150 different lines with particular HLA haplotypes would be required to 
cover ~93% of potential UK recipients27. With the advent of iPSC technology, the latter issue will be 
addressed by derivation of hiPSC lines from individuals homozygous for common HLA loci. An inter-
national effort is currently underway to address this28, but the issues of line-to-line variation and genetic 
stability of hESC and iPSC lines will remain29.
In accordance with GMP standards applicable to the sourcing and the application of raw materials 
used during production processes, such as hESC/iPSC cell derivation and differentiation into desired cell 
types, there is emerging evidence that equal scrutiny should be undertaken to account for the genetic 
health of cells at all stages of production3,30. Some characteristics of self-renewal and multipotency that 
define pluripotent stem cells (PSCs) are also shared by tumour stem cells31. This has been exemplified 
by the identification of non-random genetic changes, particularly gains of chromosomes 12, 17 and 
X, common to embryonal carcinoma cell lines and PSCs following prolonged culture26,32. Moreover, 
recent studies using high-resolution single nucleotide polymorphism (SNP) analysis of PSCs have shown 
copy number variations (CNVs) that can lead to gene expression alterations functionally linked to can-
cer33. One such microduplication associated with oncogenic transformation was detected on chromo-
some 20q11.2134,35. A comprehensive survey of 125 different PSC lines from many different laboratories 
across the world showed that about one third of lines acquired a culture-induced genomic variation 
upon prolonged culture, the most common of which was chromosome 20q11.21 microduplication36. The 
anti-apoptotic gene, BCL2L1, within this region has been shown to be a driver of growth advantage36,37. 
In addition to anomalies acquired during self-renewal, the process of in vitro differentiation from genet-
ically healthy PSCs can also lead to genomic instability38.
However, most CNVs are benign and relatively large duplications and deletions (> 100 kb) are com-
mon in healthy individuals39. Such parent-of-origin CNVs will also be present in blastocysts and hESC 
lines derived from them. The ideal way to determine if a CNV identified in a hESC line is naturally 
occurring is to genotype the parents of the donated blastocyst. This is indeed possible in cases involving 
Derivation Centre EUTCD Grade Cell Lines Number
King’s College London1 KCL031, KCL032, KCL033, KCL034, KCL037, KCL038, KCL039, KCL040 8
The University of Manchester Man11, Man12, Man13, Man14, Man15, Man16 6
Newcastle University NCL14 1
Roslin Cells Ltd, Edinburgh RC9, RC11, RC12, RC13, RC14, RC15, RC16, RC17 8
The University of Sheffield
MasterShef1, MasterShef2, MasterShef3, MasterShef4, MasterShef5, MasterShef6, 
MasterShef7, MasterShef8, MasterShef10, MasterShef11, MasterShef12, MasterShef13, 
MasterShef14, Shef3.2, Shef6.1
15
Total 38
Table 1.  List of 38 EUTCD compliant (clinical-grade) hESC lines. The 25 hESC lines analysed by SNP 
analysis are shown in bold. 1All eight (8) of the KCL hESC lines are listed on the NIH Stem Cell Registry 
(escr.nih.gov) making them available for NIH-funded projects in the USA.
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preimplantation genetic diagnosis40. However, the vast majority of blastocysts, including all within the 
UK, are donated under conditions that prohibit access to parental DNA. An alternative method to deter-
mine if a particular CNV observed in a hESC cell line might be parent-of-origin is to compare it to 
known CNVs present on the Database of Genomic Variants (DGV)41. The DGV has catalogued a collec-
tion of published CNVs from over 14,300 healthy individuals. Although not exhaustive, the collection is 
highly curated and covers a significant number of CNVs and other genomic structural variants known 
to exist in the general population. However, if a hESC CNV is found to be present on this database it 
does not exclude the possibility that it is a de novo genomic alteration that arose during development of 
the blastocyst or during establishment and maintenance of the cell line.
As well as CNVs, copy-neutral loss of heterozygosity (CN-LOH) represent another form of genomic 
structural variation characterised by a stretch of homozygosity along part of a chromosome42. If the 
affected alleles contain recessive mutations or lie within regions of the genome subject to imprinting, 
there can be either a net loss or a net gain of gene function and expression42. CN-LOH regions can also 
be due to the presence of persistent ancestral recombination ‘cold spots’ or be the consequence of recent 
consanguinity43,44. While these changes would be considered parent-of-origin if found in hESC lines, there 
are examples of somatic or acquired CN-LOH regions found during the progression of many cancers, 
particularly those of haematopoietic origin45. Whole genome SNP arrays are useful to detect CN-LOH 
events instead of regions, and regions greater than 1 Mb in length warrant further investigation42.
In this study, we sought to examine the genetic integrity of 25 clinical-grade hESC lines utilising 
whole-genome SNP genotyping analysis. While karyology is sufficient for establishing genetic normalcy 
within current regulatory standards, advances in technology and an increasing cytogenetic knowledge 
base demand higher resolution investigation of cell lines and cell products designed for clinical use.
Results and Discussion
Human ES cell lines were cultured in feeder-free conditions prior to the isolation of genomic DNA 
(Fig. 1). The DNA from 25 hESC lines (Table 1) was assayed for single nucleotide polymorphisms (SNPs) 
using the Illumina HumanCytoSNP-12 array and data was analysed for large CNVs with GenomeStudio 
and KaryoStudio software. Our SNP analysis of 25 clinical-grade hESC lines found 15 unique CNVs 
greater than 100 kb and 3 CN-LOH regions greater than 1 Mb in size among 16 hESC lines, with results 
summarised in Table 2. Nine clinical-grade hESC lines did not harbour any structural genomic variants 
of this size. The percentage of cell lines we found to have CNVs greater than 100 kb (72%) is in agreement 
with the percentage of healthy individuals (~70%) in the population found to harbour CNVs of at least 
this size39. Additionally, the percentage of cell lines with CN-LOH events between 2.5 and 5 Mb (12%) is 
similar to the percentage of individuals in outbred populations with CN-LOH of this size range43. Since 
we have restricted our search to large structural changes, we are reporting a considerably lower number 
of CNVs and CN-LOH regions identified in other studies that have examined hESC or hiPSC lines33,36,46. 
Approximately 5%–10% of the normal human genome contains CNVs averaging a few kilobases in 
Figure 1. Culture of 3 clinical-grade hESC lines. (A) Man11, Man12, and Shef6 hESCs were cultured in 
Laminin-521 in Essential 8 medium prior to collection of genomic DNA. (B) Human ESC lines maintained 
expression of the pluripotent marker, NANOG, during expansion. Scale bar, 90 μm.
www.nature.com/scientificreports/
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length47, and high resolution arrays can produce large data sets dominated by such naturally occurring 
small events48,49. Thus, we chose to use the HumanCytoSNP-12 array and KaryoStudio software, tailored 
to identify CNVs greater than 75 kb and CN-LOH regions greater than 1 MB, a resolution adequate for 
common molecular cytogenetic interpretation and applicable in a clinically relevant setting42,49–51.
Of the 15 unique CNVs detected, 12 were heterozygous duplications, 2 were heterozygous deletions, 
and 1 was a homozygous deletion (Table 2). We asked whether these structural genomic variants were 
hESC Line Passage
Detected 
Region Variation Start (bp)1 End (bp)
Length 
(kb)
# 
SNPs Genes
KCL031 21 8q24.23 Loss2 136718037 136837768 119.7 20 NONE
KCL032 7 5p14.3 Gain 19086546 21585311 2498.8 252 CDH18 
KCL033 17 5p14.3 Gain 19031726 21440254 2408.5 256 CDH18 
KCL033 17 12p11.21 Gain2 31116366 31248444 132.1 19 NONE
KCL034 19 6p22.1 Gain 27627265 27958049 330.8 13
HIST1H2BL; HIST1H2AI; HIST1H3H; HIST1H2AJ; 
HIST1H2BM; HIST1H4J; HIST1H4K; HIST1H2AK; 
HIST1H2BN; HIST1H2AL; HIST1H1B; HIST1H3I; 
HIST1H4L; HIST1H3J; HIST1H2AM; HIST1H2BO;  
OR2B2; OR2B6 
KCL037 8 18q23 Gain 78611768 79153453 541.7 84 SALL3; ATP9B 
KCL040 21 2q11.1-11.2 CN-LOH 94871756 98412364 3540.6 345
TEKT4; MAL; MRPS5; ZNF514; ZNF2; PROM2; KCNIP3; 
FAHD2A; TRIM43; ANKRD36C; GPAT2; ADRA2B; 
ASTL; DUSP2; STARD7; TMEM127; CIAO1; SNRNP200; 
ITPRIPL1; NCAPH; NEURL3; ARID5A; KANSL3; FER1L5; 
LMAN2L; CNNM4; CNNM3; ANKRD23; ANKRD39; 
SEMA4C; FAM178B; FAHD2B; ANKRD36; ANKRD36B; 
COX5B; ACTR1B; ZAP70; TMEM131; VWA3B; CNGA3 
KCL040 21 12p11.21 Gain2 31116366 31248444 132.1 19 NONE
KCL040 21 16p11.2 Loss2 32491547 33993220 1501.7 34 TP53TG3; TP53TG3C; TP53TG3B
Man11 21 15q25.3 Gain2 85376921 85597560 220.6 39 AKAP13
MasterShef2 18 17q21.31 Gain2 46138530 46710944 572.4 22 KANSL1; LRRC37A; ARL17B; LRRC37A2; ARL17A; NSF 
MasterShef3 22 6q27 Gain2 167908790 168175598 266.8 59 MLLT4; KIF25; FRMD1 
MasterShef3 22 17p11.2 Gain 21358248 21593333 235.1 31 KCNJ12; C17orf51 
MasterShef5 37 12q21.31-21.33 CN-LOH 85929477 89347087 3417.6 397 MGAT4C; C12orf50; C12orf29; CEP290; TMTC3; KITLG 
MasterShef7 16 14q21.3 Gain 46731743 47047175 315.4 18 MDGA2 
MasterShef7 16 16p11.2 Gain 29672266 30188484 516.2 94
QPRT; C16orf54; ZG16; KIF22; MAZ; PRRT2; PAGR1; MVP; 
CDIPT; SEZ6L2; ASPHD1; KCTD13; TMEM219; TAOK2; 
HIRIP3; INO80E; DOC2A; C16orf92; FAM57B; ALDOA; 
PPP4C; TBX6; YPEL3; GDPD3; MAPK3; CORO1A 
MasterShef11 17 19p12 Loss2,3 20423851 20532555 108.7 9 NONE 
Shef6 45 8p22 Gain 14634612 15188066 553.5 93 SGCZ 
RC9 17 8q24.23 Loss2 136718037 136837768 119.7 20 NONE
RC11 18 2p16.2-16.1 CN-LOH 53624707 57243565 3618.9 499
GPR75-ASB3; CHAC2; ERLEC1; GPR75; PSME4; ACYP2; 
TSPYL6; C2orf73; SPTBN1; EML6; RTN4; CLHC1; 
RPS27A; MTIF2; CCDC88A; CFAP36; SMEK2; PNPT1; 
EFEMP1; CCDC85A 
RC17 17 12p13.31 Gain2 7847740 7992065 144.3 20 SLC2A14; SLC2A3
KCL038 9 NONE
KCL039 8 NONE
Man12 20 NONE
MasterShef4 35 NONE
MasterShef8 19 NONE
MasterShef10 22 NONE
MasterShef12 16 NONE
MasterShef13 11 NONE
MasterShef14 13 NONE
Table 2.  Summary of SNP array analysis of clinical-grade hESC lines. 1Nucleotide numbers refer to 
Human Genome Build 38. 2denotes that the frequency of this CNV in the human population has been 
estimated (Supplementary Table S2). 3denotes a homozygous deletion.
www.nature.com/scientificreports/
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likely to be parent-of-origin CNVs, that is, naturally occurring, or if they could have arisen during the 
hESC derivation process or during expansion in culture. We first checked each CNV on the DGV (http://
dgv.tcag.ca) to determine whether the CNVs have been previously observed in healthy individuals41,52.
Amongst the 15 large hESC CNVs, we found 10 had clear evidence of being present in healthy indi-
viduals. For example, a duplication of 267 kb on chromosome 6q27 observed in MasterShef3 containing 3 
protein-encoding genes—MLLT4, KIF25, FRMD1—was represented on the DGV and has been reported 
in the healthy population at a frequency of over 1 in 50 individuals (Fig.  2A) 48,51,53. RC17 hESCs har-
boured a single 144 kb duplication on chromosome 12p13.31 encompassing the SLC2A14 and SLC2A3 
genes (Fig.  2B). Although this is close to the NANOG locus, we do not believe it confers a growth 
advantage since this CNV is commonly found (1 in 25) in healthy individuals39,51,54. A 132 kb duplica-
tion on chromosome 12p11.21 was detected in both KCL033 and KCL040 hESC lines (Supplementary 
Fig. S1). This region does not contain any protein-coding genes, and there are at least 14 submissions 
of this duplication on the DGV39,51,53–55. Man11, MasterShef2, and MasterShef7 also harboured genomic 
duplications of greater than 100 kb that are represented on the DGV (Supplementary Fig. S1). Man11 
harboured a 220 kb gain on chromosome 15q25.3 that has been reported several times39,51,56. This dupli-
cation contains one gene, AKAP13, and this CNV was not found in the sibling hESC line, Man12. One 
of the CNVs detected in MasterShef7, a 315 kb duplication present on chromosome 14q21.3, contains a 
single gene, MDGA, and this CNV is also present on the DGV51. A 572 kb gain on chromosome 17q21.31 
encompassing 5 genes in MasterShef2 was also found to be present in the normal population at high 
frequency (9.8%)53.
Both heterozygous deletions and the homozygous deletion were found to be naturally occurring in 
the human population. Two unrelated cell lines, KCL031 and RC9 hESCs harboured the same 120 kb 
deletion on chromosome 8q24.23 (Fig. 3). This CNV is estimated to have a frequency of about 1 in 26 
people and has been reported numerous times to occur in healthy individual39,48,51,53,55,56. This region 
does not contain any protein-coding genes. KCL040 and MasterShef11 also possessed genomic deletions 
greater than 100 kb that were present on the DGV (Supplementary Fig. S2). KCL040 harbours a previ-
ously reported 1.5 Mb deletion on chromosome 16p11.2 that contains 3 related genes56,57. MasterShef11 
has a 109 kb homozygous deletion on chromosome 19p12 that has been widely reported to occur in 
healthy individuals (~1 in 9) and does not contain any genes39,48,51,55,56.
We identified a novel 2.4 Mb gain on chromosome 5p14.3, containing a single gene, Cadherin-18, that 
was present in two sibling cell lines, KCL032 and KCL033 (Fig.  4), but not in KCL034, a third sibling 
line20,58. A duplication of this size has not been reported to date, but its presence in two sibling hESC 
lines strongly suggests it was inherited from one of the parents of the donated blastocysts rather than by 
acquisition of an identical CNV during hESC derivation and culture.
The remaining 5 CNVs, all duplications, were not fully represented on the DGV. For example, a 
516 kb duplication was detected on chromosome 16 in MasterShef7 hESCs that encompassed over 20 
genes (Fig. 5). A similarly sized duplication of this region has not been reported to date, but the DGV 
is not exhaustive and this CNV may represent a novel, but rare naturally-occurring genomic variant. 
This duplication is not known to confer a selective growth advantage, and has not been reported to be 
associated with hESC culture adaptation36. We also checked this CNV on the DECIPHER database59 of 
microdeletion and microduplication clinical syndromes to determine if it was associated with a known 
disorder. This CNV was not associated with a described clinical syndrome, nor were any of the other 14 
CNVs identified here.
The four other unique CNVs that were not fully represented on the DGV were present in KCL034, 
KCL037, MasterShef3, and Shef6 hESC lines (Supplementary Fig. S3). KCL034 harboured a duplication 
of a 331 kb region on chromosome 6 (chr6q22.1) that contained part of the Histone 1 gene cluster. 
While this region was not fully present on the DGV, it is probable that this gain represents a benign 
event as other histone clusters have been shown to be preferentially duplicated during evolution60. A 
542 kb gain on chromosome 18q23 in KCL037 containing two coding genes, SALL3 and ATP9B, has 
not been previously reported. However, a smaller duplication covering the same two genes has been 
observed51. A 235 kb duplication was detected on chromosome 17 in MasterShef3 hESCs. Although, a 
duplication of this size is not present on the DGV, four slightly smaller duplications of the region have 
been reported39,51,53,55. A 553 kb gain on chromosome 8p22 in Shef6 hESCs within an intron of the SGCZ 
gene is an unreported novel structural duplication, but a deletion of this region has been observed51. 
While the 5 novel CNVs detected in our study were not fully present on the DGV, they were also not on 
the ‘ESC-associated’ culture-adaptation list of CNVs from the International Stem Cell Initiative survey 
of 125 different hESC and hiPSC lines36. Based on the available evidence, these CNVs likely represent 
novel, but rare, structural variants found in the human population. However, we do not know the health 
status of the individuals that may harbour these novel CNVs, so we cannot assume they are benign. 
Furthermore, we cannot definitively exclude the possibility that these CNVs arose during blastocyst 
development or during the early stages of hESC line derivation.
In addition to the 15 CNVs identified, our analysis detected 3 regions of CN-LOH greater than 1 
MB among three different hESC lines, KCL040, MasterShef5, and RC11 (Table 2 and Fig. 6). All three 
regions ranged in size between 3.4 and 3.7 Mb, two of which were on chromosome 2 and the other on 
chromosome 12. Due to their interstitial nature and relatively small genetic size, it is unlikely any of these 
CN-LOH regions would represent examples of acquired CN-LOH. The vast majority of CN-LOH events 
www.nature.com/scientificreports/
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Figure 2. Duplications found in hESC lines that are present on the DGV. (A) Chromosome 6 ideograms 
from SNP array analysis of MasterShef3 revealed a 267 kb duplication near the telomere, which contained 3 
genes, MLLT4, KIF25, and FRMD1. Duplications of this size, or greater, have been reported and annotated 
on the DGV with an estimated frequency of 2.82% in the human population. (B) A 144 kb duplication 
was observed on chromosome 12p13.31 of RC17 hESCs. This region contained two genes, SCL2A14 and 
SLC2A3, and is represented on the DGV (3.9% frequency in humans).
www.nature.com/scientificreports/
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documented in cancers are telomeric in nature and while examples of acquired interstitial CN-LOH 
do exist61,62, the double recombination event required to achieve this would be difficult to explain for 
sizes less than 25 Mb63,64. Since hESCs are known to maintain monoallelic expression in some imprinted 
regions65, we cross-referenced the 3 CN-LOH regions we identified to the Genomic Imprinting data-
base (http://www.geneimprint.com)66. None of the CN-LOH regions reside in known imprinted regions, 
although CCDC85A in the CN-LOH of RC11 is predicted, but not validated, to be an imprinted gene 
on this database.
While none of the CNV and CN-LOH regions observed in the hESCs appear to harbour genomic 
anomalies associated with culture adaptation at the passages reported here (Table 2), we have detected 
the presence of the culture-adapted microduplication on chromosome 20q11.21 at higher passages of 4 
Figure 3. A common deletion observed in two unrelated hESC lines. Chromosome 8 ideograms from 
SNP array analysis of KCL031 and RC9 hESC lines revealed a 120 kb deletion on chromosome 8q24.23 (red 
arrow). This deletion is relatively common in the human population (3.85%), and does not contain any 
protein-coding genes.
www.nature.com/scientificreports/
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clinical-grade hESC lines. This microduplication was reported to be found in ~20% of research-grade 
hESC lines36,37. Thus, it is with prudence that each cell line should be re-evaluated frequently and cer-
tainly before the production of any differentiated cell product67. These results also illustrate that the het-
erogeneity of molecular karyotypes in the human population will be reflected in the cell lines produced 
from human embryos. A perfect genome is unlikely to exist, so an appreciation of human genomic diver-
sity will lend itself to a more measured interpretation of molecular karyotype and genome sequencing 
data of cell lines destined for clinical use.
Our molecular karyotypic evaluation of 25 clinical-grade hESC lines has established a valuable plat-
form for the development and manufacture of cell therapy products for clinical application in regener-
ative medicine.
Figure 4. An identical duplication found in sibling KCL hESC lines, but not present on the DGV. 
Chromosome 5 ideograms from SNP array analysis of KCL032 and KCL033 hESC lines with the common 
CNV indicated by blue arrows. This 2.4 Mb duplication on chromosome 5p14.3 included the CDH18 gene. 
A duplication of this size was not present on the DGV, but a smaller duplication (nsv597424) covering most 
of the CDH18 exons was present, and a number of smaller deletions have been observed in this region. Only 
published CNVs greater than 100 kb are represented here.
www.nature.com/scientificreports/
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Materials and Methods
Clinical-grade hESC Samples. Approval for the use of all hESC lines used in this study was granted 
by the MRC Steering Committee for the UK Stem Cell Bank and for the Use of Stem Cell Lines. The fol-
lowing clinical-grade hESC lines were kindly provided by the following derivation centres: The University 
of Sheffield (12 lines) MasterShef2, MasterShef3, MasterShef4, MasterShef5, MasterShef7, MasterShef8, 
MasterShef10, MasterShef11, MasterShef12, MasterShef13, MasterShef14 and Shef6; King’s College 
London (8 lines) KCL031, KCL032, KCL033 KCL034, KCL037, KCL038, KCL039, and KCL040; Roslin 
Cells Ltd (3 lines) RC9, RC11, and RC17; and Central Manchester NHS Foundation Trust/The University 
of Manchester (2 lines) Man11 and Man12. Most of the cell samples were provided as frozen cell pellets, 
which were directly processed for genomic DNA isolation. However, Man11 and Man12, sibling hESC 
lines, were provided as cryopreserved hESC lines, and Shef6 was obtained directly from the UK Stem 
Cell Bank (UKSCB Accession No. R-05-031). These three lines were thawed and cultured in Essential 8 
media (Life Technologies) on Laminin-521 substrate (Biolamina) for less than 10 passages before pellet-
ing by centrifugation for genomic DNA isolation. Human ES cell morphology and pluripotent marker, 
NANOG, expression were maintained during this expansion (Fig.  1). NANOG immunostaining was 
performed with anti-NANOG antibody (1:500) from R&D Systems (cat no. AF1997).
Figure 5. A novel duplication observed in MasterShef7. A 516 kb duplication on chromosome 16p11.2 
was detected in MasterShef7 by SNP array analysis. This region contained 26 protein-coding genes, and 
a duplication of this size has not been reported to date. Smaller duplications have been observed in this 
region, including a duplication (esv2758642) spanning 7 of the genes. Only published CNVs greater than 
10 kb are represented here.
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Isolation of Genomic DNA. Genomic DNA was isolated from cell pellets using the MasterPure™ 
Complete DNA and RNA Purification Kit (Epicentre) according to the manufacturer’s instructions. 
Briefly, cell pellets were lysed with Tissue and Cell Lysis Solution, followed by Proteinase K and RNase 
A treatment. Proteins were precipitated with MPC Protein Precipitation Reagent and removed by cen-
trifugation. Genomic DNA was precipitated with isopropanol, pelleted by centrifugation and then resus-
pended in TE buffer to a final concentration of 50 ng/μ l. Purity was checked by spectrophotometry using 
the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific).
HLA typing. All samples were subjected to HLA typing at the Histocompatibility and Immunogenetics 
(H&I) Laboratory of the Scottish National Blood Transfusion Service (SNBTS). The HLA typing data 
(Supplementary Table S1) was used for identification purposes by comparing it to the HLA typing data 
for each cell line provided by the hESC derivation centres. The H&I Laboratory at SNBTS is accredited 
through Clinical Pathology Accreditation (UK) Ltd (CPA), and all CPA labs are subjected to UK National 
External Quality Assessment Schemes (UK NEQAS).
Genotyping and Analysis. Genomic DNA samples were assayed using the Illumina 
HumanCytoSNP-12 v2.1 BeadChip, at either AROS (Aarhus, Denmark) or the Wellcome Trust Clinical 
Research Facility (Edinburgh, UK). The data have been deposited in NCBI’s Gene Expression Omnibus 
and are accessible through GEO Series accession number GSE68508. Genotyping was initially assessed 
using GenomeStudio genotyping module (v1.94, Illumina). KaryoStudio (v1.4, Illumina) was employed 
to perform automatic normalisation and to identify genomic aberrations utilising default settings of the 
built-in cnvPartition algorithm (3.07, Illumina) to generate B-allele frequency and smoothened Log R 
ratio plots for detected regions. These parameters are designed to detect CNVs greater than 75 kb and 
CN-LOH regions larger than 1 MB with a confidence value greater than 35. All identified duplication 
and deletions were first cross-matched to the Database of Genomic Variants (DGV; http://dgv.tcag.ca) 
to identify naturally-occurring structural variations in the human genome41,52. We also determined the 
Figure 6. Interstitial CN-LOH regions detected in clinical-grade hESC lines. Chromosome ideograms 
from SNP array analysis showing CN-LOH regions indicated by green arrows: (A) A 3.6 Mb region on 
chromosome 2p16.2-16.1 in RC11. (B) A 3.5 Mb region on chromosome 2q11.1-11.2 in KCL040. (C) A 
3.4 Mb region around chromosome 12q21.31-21.33 in MasterShef5.
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estimated frequency of 8 common CNVs in the human population (Supplementary Table S2) by access-
ing the DGV Gold Standard track of a highly curated and accurate CNV map of the human genome47. 
All CNVs were inputted into the DECIPHER database (https://decipher.sanger.ac.uk/) to determine if 
they were associated with any clinical syndromes59. The CN-LOH regions were cross-referenced with 
the Genomic Imprinting database (http://www.geneimprint.com) to determine if the genomic variants 
occurred in known imprinted regions66. CNVs that were not identified on the DGV were then checked 
against a list of ES cell-associated culture adaptation genomic variants published by the International 
Stem Cell Initiative36.
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